CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY : comparemela.com

Please disregard the headline "Gilead Sciences Proposed to Acquire CymaBay for $32.50 Per Shr in Cash or a Total Equity Value of $4.3B," at 4:46 p.m. ET. The...

Related Keywords

, Gilead Sciences Proposed To Acquire Cymabay , Sciences Proposed , Acquire Cymabay , Total Equity Value , Article Normal , Biotechnology Services , Pharmaceuticals , Healthcare Life Sciences , Biopharmaceuticals , Synd , Cymabay Therapeutics , Cbay , Us23257d1037 , Us3755581036 , Gild , Healthcare , Life Sciences ,